Notice: Undefined variable: id_or_email in /home2/ddkgfrmy/public_html/ayurvedsutra/wp-content/themes/AYU/content-single.php on line 45
Notice: Undefined variable: size in /home2/ddkgfrmy/public_html/ayurvedsutra/wp-content/themes/AYU/content-single.php on line 45
Notice: Undefined variable: default in /home2/ddkgfrmy/public_html/ayurvedsutra/wp-content/themes/AYU/content-single.php on line 45
Notice: Undefined variable: alt in /home2/ddkgfrmy/public_html/ayurvedsutra/wp-content/themes/AYU/content-single.php on line 45
By Team Ayurved Sutra
Posted on
Mateon Therapeutics to initiate commercialization of COVID-19 Ayurveda med in India
Mateon Therapeutics has announced that ArtiShield is now approved for manufacture and marketing by the Ministry of AYUSH, for the treatment of various symptoms like fever and inflammation. ArtiShield is in co-development with Windlas Biotech, Mateon’s commercial partner for India. ArtiShield is being evaluated against COVID-19 in ARTI-19- a phase IV study in India. ArtiShield is the Ayurveda – DvipaantaraDamanaka- and is labelled as capsule containing Artemisia absinthium Powder 500mg.
Related posts:
AIIA collaborates with Nisarga Herbs to conduct India’s first clinical trial on prevention of Covid-19 with Neem capsules
210-bedded Ayush Covid care centre in Mysuru
Dalmia Healthcare Starts Clinical Trial with its Ayurvedic Composition to Treat COVID-19
Government plans to set up All India Institute of Ayurveda on Konkan coastline
Ayurveda, social enterprises courses attract New Zealand students to India
